News

As part of the agreement, Oxford BioMedica will develop and supply lentiviral vectors used by Orchard for the manufacture of ex-vivo gene therapy products in primary immune deficiency disorders and

Accucaps develops and manufactures over-the-counter (OTC), high potency and conventional pharmaceutical softgels. The companies did not disclose the financial details of the transaction, which is subject to approval from the Canadian

Under the terms of the purchase agreement, Patheon will acquire the site for an immaterial sum, plus the cost of associated inventory and spare parts. Patheon has also

The agreement licenses Mylan to produce and market a generic version of Bristol-Myers Squibb's DAKLINZA (daclatasvir) Tablets, 30 mg and 60 mg, for distribution in 112 low and middle

In this trial, IV meloxicam achieved the primary endpoint of a statistically significant difference in Summed Pain Intensity Difference (SPID) over the first 24 hours (SPID24), compared to

Merck is seeking approval of Keytruda at a fixed dose of 200 mg every 3 weeks. The application includes data from five uncontrolled, open-label, multicohort, multisite phase I/II

As reported in this week’s Nature Medicine, scientists based at the Cancer Research UK Man­chester Institute, Manchester, UK (CRUK MI), demonstrated that genetic patterns found in blood-borne cancer

Rexista is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.  The submission is

The candidate vaccine is a non-live, recombinant vaccine to help prevent shingles and its complications. The phase III clinical trial programme showed that by reducing the incidence of